Company Overview 

Afferent Corporation aims to establish a leadership position in the emerging field of neurotherapeutic devices by pioneering the development of a new class of noninvasive and minimally invasive medical devices to treat chronic neurological dysfunction.

Founded in January 2000 by Jason D. Harry, Ph.D., Afferent is commercializing a breakthrough technology developed initially by James J. Collins, Ph.D., of Boston University. The technology directly enhances the function of sensory cells. This ongoing boost of information-rich sensory information constitutes a unique pathway for accessing the central nervous system (brain and spinal cord), and provides a means of treating a wide range of neurological problems.

Afferent is a privately held company, with funding from private equity, venture capital, and strategic partnerships. Notably, the National Institutes of Health have provided $2.5 million in research grant funding to pursue important clinical applications of the technology. In early 2007, Stryker Corporation made an investment in Afferent and initiated a strategic partnership.

The Company has a team of dedicated medical device professionals, representing several decades of collective business and scientific expertise. Afferent is well positioned to capitalize on its intellectual property assets, business development experience, and research and development strengths to build a company of enduring value and products that will change the lives of patients.